

INDEX

- Acetaminophen, 66
- Acetylcholine, 216, 251, 299
- Acidosis, metabolic, 221
- Aconitase, 37–39
- Acrolein, 9
- Activator protein-1 (AP-1), 7–8, 12, 20, 22–23, 73, 105, 107, 378
- Activin, 176, 181
- Acylation, 204
- Acyl-CoA cholesterol acyltransferase, 109
- Adduct formation, 9
- Adenoma, 220
- Adenomyosis, 220
- Adenosine diphosphate (ADP), 24, 84, 140, 157, 211
- Adenosine monophosphates (AMP), 157
- Adenosine triphosphate (ATP)
 - antioxidants and, 212, 286, 288
 - binding cassette proteins (ABCA1/ABCG1), 56
 - caloric restriction and, 84–85
 - cardiovascular disease, 157
 - cellular redox regulation and signaling, 202
 - depletion, 104
 - functions of, 9, 24
 - mitochondrial diseases, 34–35, 37, 40
 - neurotraumatic and neurodegenerative diseases, 52, 54, 59, 112, 119, 125
 - Parkinson disease, PD, 140
 - redox sensing, 363
 - synthase, 34
 - synthesis, 120
- Adenylation, 9
- Adhesion molecules, 106, 176, 181, 377
- Adipose tissue, 87, 122
- Adrenalectomy, 120
- Adrenal glands, 122, 184
- Adult respiratory distress syndrome, 310
- Advanced glycated end products (AGEs), 26–27, 84, 86, 156
- Aedes aegypti*, 267
- Aerobic metabolism, 37
- Age-related memory impairment (ARI studies)
 - common misconceptions, 348–349
 - defined, 347–348
 - influential factors, 347–349, 353–354
 - interventions, types of, 354–355
 - multiple phases of, 355
- AGI-1067, 215
- Aging process
 - diet and, 212–213
 - environmental stressors, 185
 - honeybees, 285
 - influences on, 20, 93
 - memory impairment, 347–349
 - mitochondrial dysfunction and, 85–86
 - neurodegenerative diseases and, 302
 - olfactory dysfunction, 299, 302, 382
 - oxidative stress role in, 355–356
 - preventive effects on, 90
 - reactive oxygen species (ROS), 272–273
 - vertebrates compared with invertebrates, 169–170
- Aging theories
 - free radical/oxidative stress, 168–169
 - overview of, 167–168
- AhpD protein, 339
- AIDS dementia complex, 111
- Air pollution, 183
- AKH/RPCH (adipokinetic hormone/red pigment concentration hormone), 264–266
- Akt, 252, 264, 339
- Alanine, 72
- Albumin, 94
- Alcohol, generally
 - consumption, 213, 223
 - dehydrogenase, 122
- Aldehydes
 - antioxidants and, 216, 219–220
 - caloric restriction and, 92, 96
 - cellular redox regulation and signaling, 196
 - endocrine control and, 266
 - functions generally, 25–27
 - in neurotraumatic and neurodegenerative diseases, 54, 108
 - reactive oxygen species (ROS) generation, 9
- Alkoxyl radicals, 3, 52, 104, 377
- Allelochemicals, 262
- Allopurinol, 157, 159, 161–162, 224
- α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), 353
- α -Lipoic acid (ALA), 210–211, 222
- α -Synuclein, 28, 139, 142, 144, 319
- α -Tocopherol
 - antioxidants and, 214, 217, 220, 222
 - caloric restriction and, 94–96
 - functions of, 18, 28, 94–96, 263
 - Parkinson disease, PD, 140
- Alternative oxidase (AOX) pathway, 363
- Alzheimer disease (AD)
 - aging process and, 356
 - amyloid plaques, 129–132, 216
 - aneuploidy, 130–134
 - antioxidant treatment, 215–216
 - brain dysfunction, 6, 12, 341
 - caloric restriction and, 85

- Alzheimer disease (AD) (*continued*)
 cell cycle, 130–131
C. elegans model of, 352
 characteristics of, generally, 26–28
 development of, 215–216
 DNA damage, 131
Drosophila melanogaster studies, 310
 early-onset (EOAD), 131
 evidence of, 118–119
 familial (FAD), 118–120, 130
 future research directions, 379
 incidence of, 235
 inherited, 130
 late-onset (LOAD), 130
 memory impairment, 353–354
 mitochondrial DNA (mtDNA), 34, 38, 41
 neurofibrillary tangles (NFTs), 130–132, 134, 215, 236
 neurogenesis in, 131–134
 neuropathology features, 235–236
 neurosteroids in oxidative stress-mediated injury, 120–125
 neurotoxicity, 55, 58
 olfactory dysfunction, 297, 299, 303
 oxidative stress and, 133–134, 273
 pathogenesis, 103, 105, 107, 110–112, 129–131
 proteins, of cell cycle, 130–131
 red wines/wine-derived polyphenols for prevention and treatment of, 236–242
 sporadic, 118–120, 130
 treatment of, 235
- Ames test, 252
- Amino acids
 Alzheimer disease and, 117
 antioxidants and, 223, 225
 cardiovascular disease, 154
 mitochondrial diseases, 41
 neurodegenerative diseases, 117, 235
 in propolis, 246, 251
 sestrins and, 340
- Amoxicillin, 185
- AMP-activated protein kinase (AMPK), 89, 338, 341
- Amyloid, generally
 - β (A β) peptide, 117–119, 123–125, 216, 235–236, 238, 240
 characterized, 26–27
 plaques, 129–132, 216
 precursor protein (APP), 57, 118–120, 123–124, 130, 132, 134, 240
- Amyotrophic lateral sclerosis (ALS), 6, 34, 41, 103, 105, 107, 111, 215, 221, 297, 310, 379
- Androstenediol, 121, 123
- Androstenedione, 121–122
- Anesthetics, 249, 253
- Aneuploidy, 130–134
- Ang II, 7
- Angiogenesis, 89, 252
- Angiopoietin-I, 184
- Angiotensin-converting enzyme (ACE), 157
- Animal models
 Alzheimer Disease, 132–133
 environmental stressors, 186
 mitochondrial mutations, 41–42
- A9/A10 neurons, 145, 147
- Anopheles gambiae*, 280
- Anoxia
 effects of, 284
 -reoxygenation, 364
- Anthropic sensors, 361–366
- Antiapoptosis genes, 179, 181–182
- Antibiotics, 247, 253
- Antibodies, 110, 249
- Anticancer drugs, 23, 74, 247, 253
- Antiedema substances, 215
- Antigens, 56, 130
- Antiinflammatory substances, 249
- Anti-inflammatory signaling, 111
- Antimicrobial peptides (AMP), 283
- Antimicrobial substances, 273. *See also* Propolis
- Antioxidant(s)
 cycling of, 95
 environmental stressors and, 178
 enzymatic, 272, 276
 enzymes targeted to mitochondria, 41
 functions of, 6–7, 10, 18–19, 22–23, 25–26, 28–29, 84, 103, 112, 156, 161–162
 defense mechanism/response, 89, 119, 140, 160, 170–171, 176, 331, 378
 defense system (AOS), 39–40, 90, 117, 209, 284, 366
 dietary, 212–213, 215
 enzymatic mechanisms, 263, 331
 neurogenesis and, 134
 nonenzymatic mechanisms, 261, 263
 propolis, 248
 carregulation of, 40
 response element (ARE), 7–8, 63–64, 272, 283–284, 288, 309, 313, 316, 319
 supplementation of, 120, 209–210, 218
 target strategy, in mitochondria, 41
 therapies, *see* Antioxidant therapy
- Antioxidant therapy
 aging and, 212–213
 asthma, 221
 benefits of, 161–162, 209–212, 225–226
 cancer, 219–220
 cardiovascular disease, 213–215
 chronic obstructive pulmonary disease (COPD), 221–222
 complex regional pain syndrome, 218–219
 diabetes, 222–223
 ischemia-reperfusion injury, 213–215
 kidney disease, 225
 liver disease, 223
 neurodegenerative diseases, 215–218
 pancreatitis, 223–225
 pregnancy and preeclampsia, 221
 rheumatoid arthritis, 225
- Antitumor substances, 249–250
- Antiviral substances, 250, 253
- Apis mellifera*
 antioxidant system, 279–280, 289
- brain, iron in, 299–301
 olfactory dysfunction, 297–298, 302–304
 olfactory neuronal network in, 298–299
 ontogenesis and life span, 266, 284–286
 ROS regulation in, 288–289
 winter generation of, 286–288
- Aplysia* spp., 352
- Apolipoprotein E (ApoE), 56, 130, 217
- Apolipoprotein E4, 118–119
- Apoptosis
 Alzheimer disease, 119, 125, 130, 133
 antioxidants and, 285
 caloric restriction and, 90
 environmental stressors, impact of, 176, 182, 187, 190
 free radicals, 19–20, 22–23, 25
 future research directions, 382
 in mollusks, 368, 370–371
 neurodegenerative diseases, 105
 Parkinson disease, 144
 in propolis, 248, 252
 reactive oxygen species (ROS) generation, 6, 8–10, 12
- Apoptotic protease activating factor-1 (APAF-1), 11
- Apoptotic genes, 180–181
- Arabidopsis*, 331
- Arachidonic acid (ARA)
 antioxidants and, 216
 future research directions, 377–378, 380
 neurodegenerative diseases, 104, 106–111
 neurotoxicity, 52–53, 58
 olfactory dysfunction and, 302–304
 reactive oxygen species (ROS) generation, 4, 7, 16
- Arctica islandia*, 362
- Arginine, 10–11, 41, 54, 106, 160
- Argopecten irradians*, 370
- Aromatics, 25, 41, 246
- Arrhythmias, 159. *See also* Cardiovascular disease
- Arsenic, 20–21, 175, 188, 313
- Arsenite, 74, 171
- Artepillin C, 247, 251–253
- Ascorbate, 18–19, 27
- Ascorbate peroxidase (APOX), 263
- Ascorbic acid, 23, 39–40, 84, 94–95, 143, 209, 214, 220, 263. *See also* Vitamin C
- Ascosphaera* spp., 247
- Aspergillus* spp., 247
- Aspirin, 157
- Associative learning, 349–352, 355
- Asthma, 221, 272, 310
- Astrocytes, 10, 52, 56, 107, 110–111, 146
- Asymmetrical dimethyl arginine (ADMA), 155
- Ataxia, 36
- ATG, 340–341
- Atherosclerosis, etiology of, 12, 20, 23, 25–26, 83, 88, 155–156, 162, 210, 310, 379
- Atrial fibrillation, 156–157
- ATPases, 107–108, 368

- Autoantibodies, 12, 92
 Autoimmune diseases/disorders, 12, 380.
 See also Lupus erythematosus;
 Multiple sclerosis
 Autoimmune inflammation, 65
 Autooxidation, 142–144, 380
 Autophagy, 90, 176, 186, 189, 341
 Autophosphorylation, 251
 Azoxymethane/dextran sodium sulfate
 (AOM/DSS), 66
- Baccharis dracunculifolia*, 252
Bacillus spp., 247, 264
 Bacterial meningitis, 111
Bacteroides spp., 247
 Basic fibroblast growth factor (bFGF), 252
 Basic helix-loop-helix (bHLH) transcription
 factor, 327, 331
 Batten disease, 215
 Bax gene, 106
 Bayesian network techniques, 176
 Bcl-2, 11, 106, 125
 Beeswax. *See* Propolis
 Benz-starvation association, 350
 Benzaldehyde, 350
 Benzo(a)pyrene, 66
 Benzoic acid, 246, 253
 Beryllium, 20
 Beta-blocker therapy, 157
 Beta-carotene, health effects of, 23, 210, 214,
 217, 219, 222, 224–225
 β -galactosidase (lacZ), 312–313
 β -Naphthalene, 74
 Big MAPK (BMK1), 24
 Bilirubin, 84, 94
 4E-binding protein (4E-BP), 340
 Biogenesis, 90
 Bioinformatics, 328, 338
 Biomarkers, types of, 12, 91–96, 175,
 380–381
 Biomolecules, 17, 24
 Biopsy, 132, 297
 Biosynthesis, 176, 178
Blaberus discoidalis, 267
 Bladder
 cancer, 2
 tumors, 66
 BLASTn, 328
 Bleomycin-induced pulmonary fibrosis,
 64–65
 Blood-brain barrier (BBB), 55, 105, 111
 Blood pressure, 18. *See also* Hypertension
 Bone morphogenetic protein (BMP), 175
Botrytis spp., 247
 Brain
 aging process, 105
 amygdala, 217
 amyloid plaques, 130
 cancer, 12
 cerebellum, 122, 352
 cholesterol and, 56
 dentate gyrus (DG), 131–134
 dorsal root ganglia, 122
 environmental stressors, 185
 frontal cortex, 352
 mammalian, 378–379
 medulla oblongata, 74
 neurodegenerative disease and, 103–105,
 109–110, 130–131
 Nrf2 gene and, 66
 ROS generated in, 3–12
 striatum, 216–217
 substantia nigra, 216–217
 substantia nigra pars compacta
 (SNpc), 139
 subventricular zone (SVZ), 131–134
 temporal lobe, 217
 tumors, 20
 Breast cancer, 21, 23, 74, 247–248
 Bromodeoxyuridine (BrdU) labeling,
 132–133
 Bronchitis, 250
 bZIP protein, 63–64, 72
- Cadmium, 74, 171, 368
Caenorhabditis elegans
 age-related memory impairment (ARMI)
 studies, 347–349
 aging research, 167–170
 airway system, 271
 Alzheimer disease (AD) in, 352
 cognitive aging in, 349–351
 Keap1/Nrf2 signaling, 311, 315, 317, 319
 locomotory rate, 350
 neurodegenerative disease and, 353
 Nrf2-small Maf heterodimers, 64
 sestrins, 338
 Caffeic acid, 249, 253
 Calbindin proteins, 145
 Calcium/calcium channels
 Alzheimer disease, 117–118, 122,
 124–125
 antioxidant therapy and, 217
 in *Caenorhabditis elegans* studies, 351–352
 calbindin proteins, 145
 in *Drosophila melanogaster* studies, 274
 free radicals, 22, 24
 neurotraumatic and neurodegenerative
 diseases, 52, 54–55, 58, 104–105, 111
 Parkinson disease, 143, 145–147
 reactive oxygen species (ROS) generation,
 4, 6, 8–9
 Calmodulin, 22
 Caloric restriction (CR), oxidative stress
 modulation
 fasting, 90, 96
 molecular differences biomarkers, 91–96
 overview of, 89–90, 96, 355
 physical activity, 90–91
 ROS generated by food, 86–88, 96
 sex differences, 91
 sirtuins role, 88–89
 Cancer, *see specific types of cancer*
 antioxidants and, 23, 219–220
 carcinogenesis, 22–23, 175
 cellular signaling dysregulation in, 20–22
 chemotherapy, 74, 220, 247–248
 future research directions, 380
 implications of, 168, 187, 190, 310
 initiation-promotion-progression model
 of carcinogenesis, 22
 metastasis, 74
 Nrf2 functions in, 74
 Carcinoma cells, propolis-induced
 apoptosis carcinoma cells, 248
 redox environment of cell and
 carcinogenesis, 22–23
 ROS-mediated, 12
Candida albicans, 247
 Cap'n'Collar (CNC). *See* CNC protein
 Carbohydrates
 in aging process, 176
 antioxidants and, 213
 caloric restriction and, 90, 92
 endocrine system and, 263
 environmental stressors, 180
 future research studies, 382
 honeybee research, 296–297
 neurodegenerative diseases, 107
 Carbon dioxide levels, 18
 Carbonylation, 280
 Carbonyl groups, 367
 Carboplatin, 74
 Cardiac conduction block, 36
 Cardiomyocytes, 156
 Cardiomyopathy, 34, 88, 211
 Cardiovascular disease (CVD)
 aging and, 168
 antioxidant therapies, 161–162,
 213–215
 arrhythmia, 159
 atherosclerosis, 12, 20, 23, 25–26,
 83, 88, 155–156, 162, 210,
 310, 379
 atrial fibrillation, 156–157
 cardiac remodeling, 158
 development of, 20–21, 88, 91, 153,
 223, 380
 environmental stressors, 183
 future research directions, 379
 heart failure, 156–157
 heart infarction, 41, 156–157, 214
 hypercholesterolemia, 25–26, 222
 hypertrophy, 158
 interstitial fibrosis, 158–159
 ischemic phase, 157
 mitochondrial dysfunction and, 24–25
 prevention strategies, 23, 160–161
 reperfusion phase, 157–158
 risk factors, 213
 Cardiovascular system, 187, 382. *See also*
 Heart
 Carnitine, 40
 Carotenoids, 22–23, 209, 263. *See also* Beta-
 carotene
 Carotid arteries, 25
 Carpal tunnel syndrome (CTS), 210
 Carrageenin, 66
 Casein kinase 2 (CK2), 331, 333
 Caspases, 10, 57, 66, 106, 110, 176, 181–182,
 252, 369
 Catabolism, 340

- Catalase (CAT)
aging process and, 170
antioxidants and, 283–284, 288
caloric restriction, 84, 86, 93–94
cardiovascular disease, 154, 160
Drosophila melanogaster research, 271, 273–274, 276, 329, 331
endocrine system and, 263, 266
free radicals, 17, 23
mitochondrial DNA (mtDNA) mutations, 34, 39–41
neurodegenerative diseases, 113
Parkinson disease, 143
reactive oxygen species (ROS)
generation, 5, 8
sesstrins and, 337
Catalysis, 195, 367
Catecholamines, 117–118, 142–144, 261, 302
Catechins, 214
Catechols, 142, 144
Cations, lipophilic, 41
Cell adhesion, 20
Cell cycle
Alzheimer disease, 130–131
antioxidants and, 285
environmental stressors, 176, 178–180, 187, 189
free radicals, 22
future research directions, 380–381
Nrf2-small Maf heterodimers, 75
in propolis, 247–248
reactive oxygen species (ROS), 6–7, 12
Cell death. *See* Apoptosis
Cell differentiation, 21, 178, 285
Cell growth, 177–178
Cell proliferation, 21–22, 75, 176, 178, 180, 248, 377
Cell signaling pathways, 19
Cell viability, 10
Central nervous system (CNS), 28, 122, 216, 299, 353
Ceramides, 8, 11, 55, 57–58, 105, 109–110
Cerebrospinal fluid (CSF), 210, 216–217, 380–381
Ceruloplasmin, 94
c-Fos proteins, 8, 72–73, 111, 124
Chagas disease, 214
Chaperone-mediated autophagy (CMA), 144
Chaperone proteins, 8, 94, 272, 367, 369
Chelation, 23, 28–29, 110
Chemokines, 8, 106, 110, 112, 251, 377
Chemoprevention strategies, 75, 211
Chemotaxis, 349–350
Chemotherapy, 74, 220, 247–248
Chicago Health and Aging Study, 217
Chloramphenicol, 39
Cholesterol levels
Alzheimer disease, 121, 123
antioxidants and, 211, 213–215, 222–223
endocrine system and, 266
free radicals and, 25–26
reactive species oxygen (ROS), 12, 25–26
neurotraumatic and neurodegenerative diseases, 52, 56–57, 103, 105, 109–110
Chromatin immunoprecipitation (ChIP), 334
Chromium(III), 21
Chronic inflammatory diseases, 12
Chronic obstructive pulmonary disease (COPD), 221–222
Chronic progressive external ophthalmoplegia (CPEO) syndrome, 34, 36–37, 39–40
Chronic renal failure, 225
Cigarette smoking, health effects of, 66, 156, 186, 214, 220
Cilastazol, 222
Cinnamic acid, 253
CIP1 protein, 23
Circadian regulatory motifs, 327
Circadian transcriptional control, 334
Cisplatin, 74
Citrulline, 10–11, 54
c-Jun, 11, 72–73, 111
c-Jun N-terminal kinase (JNK), 6, 21, 23, 133, 160, 182, 339, 369
Clioquinol, 141
CLK-CYC pathway, 327–328
Clk mutations, 354
Clock proteins, 331
CNC protein, 64, 72, 311–317, 319–320, 331
Codons, 195–196
Coenzyme Q₁₀ (CoQ₁₀), 40–42, 94–95, 218, 354
Cognition, 8
Cognitive aging, 352, 355
Cognitive impairment, in Alzheimer disease characterized, 107
mild (MCI), 119, 134, 217
Colitis, 249, 310
Collagen, 158–159
Colon cancer, 21, 23, 247. *See also* Colorectal cancer
Colony Collapse Disorder, 288
Colorectal cancer, 219
Complementary DNA (cDNA), microarray analysis, 42
Complex regional pain syndrome, 218–219
Consensus E-box (CACGTG) E-box, 327, 329
Consensus sequences, 8
Copper, health impact of, 4, 12, 27–28, 34, 105, 119, 175, 210, 214, 351, 368–369
Coronary artery disease (CAD), 222
Corticoids, 121
Corticosteroids, 223
Craniofacial organs, 66
Crassostrea spp., 363, 368, 371
C-reactive protein (CRP), 212, 224
Creatine phosphokinase, 157
CREB, 124
Crohn disease (CD), 211, 249
Cross-linkage, 9
Crosstalk, 58
Curcumin, 75, 211
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazole (CDDO-Im), 66, 75
Cyclooxygenase -2 (COX-2)
antioxidant therapy and, 211
future research directions, 378
neurotraumatic and neurodegenerative diseases, 52, 54–55, 58, 106, 111–112
Nrf2-small Maf heterodimers, 66, 74
Parkinson disease, 146
reactive oxygen species (ROS) generation, 5, 7, 11
Cycloserine, 55
Cysteine
in aging process, 171
antioxidants and, 221, 225
cardiovascular disease and, 159–160
cellular redox regulation and signaling, 195–198
future research directions, 380
neurodegenerative diseases, 108
Nrf2-small Maf heterodimers, 70
reactive oxygen species (ROS), 6, 9, 20, 22
sesstrins and, 339
Cytochromes
c, 10, 34, 39, 107, 125, 248, 302, 364, 366
c oxidase (COX), 4, 12, 36–37, 90, 104, 108, 110, 117–118, 382
P450, 3, 12, 109–110, 121–122, 281
Cytokines
Alzheimer disease, role in, 132
caloric restriction and, 87
environmental stressors, 183
free radicals and, 20, 25, 27
generation of reactive oxygen species (ROS), 5, 8
in neurotraumatic and neurodegenerative diseases, 52, 104–106, 110–113
Parkinson disease, role in, 146
in propolis, 251
Cytoprotective genes, 68
Cytoskeleton, 180
Cytosol, 210, 302, 377, 379
Cytotoxicity, 23, 88, 119, 220, 247, 282
Deafness, 34
Deamination, 281
Dehydroepiandrosterone (DHEA), 120–123
Dehydrogenases, 381
Deiodinases (DIO), 200–201, 204
Deletions, 36, 67
Dementia, 217–218, 236, 297
Demyelination, 104
Dental care, 246, 250
Deoxycorticosterone (DOC), 122
Deoxyguanosine, 9, 12
Deoxyribonucleic acid. *See* DNA
Dephrenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), 146
Detoxification
enzymes, 312
Phase II detoxification response, 8
of proteins, 280

- Dexamethasone, 185
 Dexlipotam (DEX), 223
 Diabetes, etiology, 26, 83, 85, 88, 92, 95, 168, 190, 210–211, 213, 222–223
 Diabetes mellitus, 20, 34, 36, 175, 215
 Diacylglycerol (DAG), 87
 Diclofenac, 225
 Diesel exhaust, health effects of, 66
 Dihydroprogesterone (DHP), 122
 Dihydropyridines (DHPs), 146
 Dihydrotestosterone (DHT), 121–122
 Dimethyl sulfoxide (DMSO), 315–316
 Dimethyltyrosine, 41
 Dismutation reaction, 17
 Disulfide isomerase, 107
 Disulfides, 96, 107, 196–197
 Dithiolethiones, 75
 Divalent metal transporter 1 (DMT1), 141
 DJ-1 protein, 28, 142, 317–318
 DMBA/TPA, 66
 DNA
 Alzheimer Disease and, 131
 characteristics of, generally, 91, 113
 estrogen and, 124
 fragmentation, 18, 252, 368
 methylation, 74, 280
 microarray analysis, 176
 oxidation, 103, 118–119, 140, 297
 repair, 177–179, 186–187, 189
 replication, 12, 186–187
 ROS-mediated damage, 11–12
 sequences, 72–73
 synthesis, 53–54, 108, 132
 transcription, 12
 DNA polymerase gamma (POLG)
 deficiency, 41
 Dobutamine, 215
 Docosahexaenoic acid (DHA), 4, 104, 107–109, 216
 Docosanoids, 5, 104, 108, 111
 Docotrienes, 108
 DOPAC, 142, 144, 146
 Dopamine (DA), 8, 141–146, 251, 273, 302, 317–319
 Dopaminergic neurons, 139–146, 317
 Dorsal root ganglion (DRG), 111
 Dose-response relationship, 96
 Down-genes, environmental stressors, 184–186
 Downregulation, 8–9, 22, 124, 273, 342
Drosophila melanogaster
 age-associated pathologies, 341–342
 airway system, oxidative stress in, 275–276
 digestive systems, 273–274
 Cnc in development of, 311–312
 endocrine control, 267
 genome, 280
 immune system, 274–275
 modulation of oxidative stress by Keap1/Nrf2 signaling, 309–320
 nervous system, 273
 Nrf2 system, 310, 316–320
 neurodegeneration, 341
 promoter analysis study of circadian regulatory motifs, 327–334
 reactive oxygen species (ROS) 167, 170, 271
 DSS, 66
 D3T, 66
 Dual oxidase (DUOX), 274, 276
 Ear infection, 250
 Early-onset Alzheimer Disease (EOAD), 130
 E-box, promoter analysis study, 328–330, 333
 Ecdysteroids, 264, 266–267
 Ecotoxicology, 367, 371
 Ectothermy, 363
 EGF receptor (EGFR), 20
 Eicosanoids, 5, 52, 104, 108, 111
 Elastase, 66
 Elastin, 159
 Electromyographic studies, 210
 Electron paramagnetic resonance (EPR), 261
 Electron spin resonance (ESR)
 analysis, 210
 Electron transport chain (ETC), 34, 140, 144
 Electrophilicity/electrophiles, 67–71
 ELISA, 380–381
 Embryogenesis, 187
 Emphysema, 64, 310
 Encephalomyopathies, mitochondrial, 34, 37, 39
 Endocrine diseases, 24
 Endocrine system
 endocrine glands, peripheral, 120
 functions of, 352
 in insects, 264–267
 Endocytosis, 56
 Endometriosis, 220
 Endoplasmic reticulum (ER), 6, 107, 121–122, 202–203
 Endorphins, 251
 Endosulfan, 266
 Energy consumption hypothesis, 168
 Enolases, 107
 Environmental stressors
 toxicity of, 176
 types of, 130, 175
 Enzyme activities, *see specific types of enzymes*
 activation of, 7–8, 52
 modulation of, 6
 Epidemiological studies, 23, 28
 Epidermal growth factor (EGF), 20, 133, 199, 251
 Epigallocatechin gallate (EGCg), 209, 252
 Epileptic seizures, 111
 Epinephrine, 251
 Epoxygenase (EPOX), 104
Escherichia coli, 247, 370
 Essential life span (ELS), 167–168
 Esters, 246–247, 253
 Estradiols, 89, 117–118, 121–122, 124
 Estrogens, 91, 123–125, 142, 220
 Ethanol, 184, 186
 Ethnicity, as predisposition factor, 213–214
 Etoposide, 74
 EUK proteins, 41, 354
 Excitotoxicity, 55–56, 59, 103, 106–107, 111–113, 125
 Exercise, health effects of, 86, 90–91, 93, 160–161
 Exocytosis, 57
 Extracellular acidification rate (EDCAR), 37
 Extracellular oxidative stress, 175
 Extracellular signal-regulated kinase (ERK), 6, 21, 24–25, 75, 160, 262
 Extracorporeal shock wave lithotripsy (ESWL), 225
 Extract of Brazilian propolis (EEBP), 252
 Familial adenomatous polyposis, 211
 Familial Alzheimer disease (FAD), 118–120, 130
 Fatty acid coenzyme A (FA-CoA), 87
 Fatty acids
 biosynthesis, 176
 caloric restriction, 196
 free (FFA), 86
 future research directions, 382
 in neurotraumatic and neurodegenerative diseases, 54, 57
 omega-3, 221
 polyunsaturated (PUFAs), 3–4, 105, 107, 211, 215, 221, 266, 297, 299, 302, 353, 377–378
 unsaturated, 107, 117
 Fenton reaction, 17–18, 20, 25, 38, 267, 297, 370, 377
 Ferritin, 141, 263, 288, 365
 Ferrous ammonium citrate (FAC), 297, 299–301, 304
 Fibrinogen, 156
 Fibroblast growth factor, 20, 39
 Fibronectin, 184
 Fibrosis, types of, 20, 64–65, 158–159, 310
 Flavanones, 248
 Flavin adenine dinucleotide (FADH₂), 34, 84, 140, 143
 Flavoenzymes, 19
 FlyBase, 328–329
 FLYREG database, 331–332
 Flavonoids, 23, 209, 212–213, 217, 239, 246, 249, 253
 5-Fluorouracil, 74
 Fly studies. *See Drosophila melanogaster*
 Food and diet
 aging process and, 212–213
 ROS generated by, 86–88
 safety, 253
 Forskolin, 184
 FoxO
 activation, 272, 275–276, 285–286
 signaling pathway, 338–339, 380
 Free Oxygen Radicals Defence (FORD), 210
 Free Oxygen Radical Testing (FORT), 210

- Free radicals, *see specific types of free radicals*
 defense against, 18
 health impact of, 153–156, 161, 168–169, 271, 304, 361, 367, 380
 liver disease and, 223
 overproduction of, 17, 42
 oxidation, 18
 oxidative stress effects, 210
 pancreatitis and, 224
 reduction of, 18
 selenoproteins and, 196
 thermodynamics of, 18
 Friedrich ataxia (FRDA), 37
 Fructose-1,6-biphosphate aldolase, 107
 F₂-isoprostanes, 92–93, 96, 108–109, 155, 380. *See also* Isoprostanes
 Fungi infection, 249
 Furanocoumarins, 262
- GABA, 122
Galanthus nivalis, 264–265
 Gallbladder cancer, 74
 γ-linolenic acid (GLA), 210–211
 Gamma radiation, 22
 Gamma-T supplementation, 215
 Gas chromatography-mass spectroscopic studies, 380–381
 Gastric carcinogenesis, 220
 Gastritis, 23, 220–221, 310
 Gastrointestinal disease, 187
 Gelatin, 159
 Gender differences, 91. *See also* Women's health
 Gene expression, *see specific genes*
 environmental stressors and, 176–190
 induction of, 283
 signatures, 186–187
 stimulation of, 52
 Gene Expression Omnibus (GEO), 183, 187
 Gene Ontology (GO), 183, 328–329, 333
 Gene Ontology for Motifs (GOMO), 328–329
 Gene therapy, 41–42
 Gene transcription, 365–366. *See also* Transcription factors
 Genes, modulation of, 6–8
 Genetic disorders, 34
 Genistein, 209
 Genotoxic stresses/genotoxicity, 338–339, 368
 Germ cells, 186
 Giardiasis, 249
Giardia spp., 247
 Glaucoma, 297
 Glial cells, 56, 111, 120, 146
 Glioblastoma multiforme, 20
 Glomerulonephritis, 225
 Glucagon, 266
 Gluconeogenesis, 89
 Glucose levels, 26, 36, 40, 105, 122, 125, 223, 283
 Glutamate, 104, 107, 110, 112, 118
 Glutamine, 224
 Glutaredoxin (GRX), 280
 Glutathione (GSH)
 antioxidants and, 224, 279, 288
 cardiovascular disease, role in, 159, 162
 in cellular redox regulation and signaling, 197–199, 201, 203
 endocrine system, 263, 265
 environmental stressors, 175
 free radicals and, 18, 23, 28
 mollusk research, 364, 368
 in neurological disease, 300–301, 303
 Nrf2-small Maf heterodimers, 75, 89, 90–91, 94–96
 Parkinson disease, role in, 140–144
 in promotor analysis, 331, 333
 in reactive oxygen species (ROS) generation 5–6, 8–9
 Glutathione disulfide (GSSG), 19, 94, 140, 197, 203
 Glutathione peroxidase (Gpx)
 antioxidant therapy and, 217, 280, 288
 caloric restriction effects, 84, 90–91, 94
 cardiovascular disease, role in, 154, 158
 cellular redox regulation and signaling, 197–203
 endocrine system and, 266
 environmental stressors, 176, 178
 free radicals and, 17, 23, 26
 future research directions, 379
 in mitochondrial diseases, 34, 39–41
 mollusk research, 365–366
 in neurodegenerative diseases, 113
 Parkinson disease, role in, 140
 in reactive oxygen species (ROS) generation, 5–6
 Glutathione reductase (GR), 5, 39, 84, 94, 273, 280
 Glutathione S-transferase (GST), 6, 65, 199, 272, 280–282, 284–285, 309, 329
 Glutathione S-transferase peroxidase (GSTPx), 263, 273
 Glutathione synthetase (GSS), 188
 Glutathionylation, 198, 200, 367
 Glycation, 110, 216, 222
 Glyceraldehyde-3-phosphate dehydrogenase (G3PD), 10
 Glycerophosphates, 55–56
 Glycerophospholipids, 52–54, 107, 110
 Glycolysis, 286
Gonyaulax polyedra, 334
 G protein
 -coupled receptors (GPCRs), 111, 274
 functions of, 251
 -regulated signaling, 124
 Grape seed polyphenols, treatment of Alzheimer disease, 235–242
 Graves disease, 220
 Growth differentiation factor (gdf), 176, 181
 Growth factors, 20, 110–111, 180, 251
 Guamanian amyotrophic lateral sclerosis (G-ALS), 297
 Guanylate cyclases, 251
- Haber-Weiss reaction, 17–18, 297, 367
Haliotis diversicolor, 371
 Hayflick limit, 168
 Head and neck cancer, 74
 Heart, *see* Cardiovascular disease
 cardiac degeneration, age-related, 342
 cardiac muscle, 341
 cardiac remodeling, 158
 chamber dilation, 159
 contractibility, 159
 failure, 23–24, 156–157
 infarction, 156–157
 Heat shock proteins (HSPs), 369, 380
 Heavy metals, 188, 313, 319, 368
 HEK cells, 107
Helicobacter pylori infection, 220–221, 247
Helicoverpa zea, 262
Helix spp., 366, 368
 Hematological disease, 187. *See also* Leukemia
 Hematologic malignancies, 331
 Hematopoietic system, Nrf2 gene and, 66
 Heme
 oxygenase (HO-1), 27, 302, 309
 synthesis, 37–38
 Hemocytes, 370
 Hemodialysis, 225
 Hemoglobin, 176
 Hepatitis, 223
 Hepatocytes, 75
 HepG2 cells, 187
 Herbicides, 262
 Heregulin, 184, 186
 Heterodimerization, 8, 72–74
 Heteroplasmy, 33, 35–36
 High-performance liquid chromatographic (HPLC) studies, 92, 210, 237, 381
 Hippocampus
 environmental stressors, 184–185
 functions of, 6, 51, 53–54, 56–57, 131, 134, 352
 Hippocrates, 167, 245
 Histidines, 9, 108, 380
 Histolysis, 284
 Histones, 133, 281
 Homeostasis, influential factors, 8–9, 17, 19, 23, 28, 38, 56, 107, 110, 113, 320
 Homolysis, 261
 Honeybee. *See Apis mellifera*
 Honolulu-Asia Aging Study, 217
 Hormones, health effects of, 20, 251, 264. *See also specific types of hormones*
 HSP70, 368
 Human genome, 198, 201–202
 Huntington disease (HD), 103, 105, 111, 117, 273, 297
 Hydrogen peroxide (H₂O₂)
 in aging process, 171
 Alzheimer disease, role in, 117, 125–126, 129
 antioxidants and, 222, 281, 283, 288–289
 caloric restriction and, 83, 85, 89–92
 cardiovascular disease, role in, 153–154, 161

- cellular redox regulation and signaling, 196
- Drosophila melanogaster* research, 274
- endocrine system, impact on, 262–263, 266
- free radicals and, 17, 19–20, 22, 25, 27
- honeybee research, 296–297
- mitochondrial diseases, role in, 34, 39
- mollusk research, 367, 370
- in neurotraumatic and neurodegenerative diseases, 52, 104–105
- Nrf2-small Maf heterodimers, 74
- Parkinson disease, role in, 140, 142, 146
- reactive oxygen species (ROS) generation, 3, 5, 8–11
- Hydrolysis, 54
- Hydroperoxides, 5
- Hydroperoxyl radicals, 168, 295
- Hydroxycholesterol, 56–57, 105, 109–110
- 8-Hydroxydeoxy-guanosine, 93
- Hydroxycedysone, 266
- 4-Hydroxyhexenal (4-HHE), 5, 108–109
- 4-Hydroxynonenal (4-HNE)
- Alzheimer disease, role in, 119
- antioxidants and, 216
- free radicals and, 25, 28
- future research directions, 380–381
- in neurotraumatic and neurodegenerative diseases, 53–55, 57, 105–109
- Nrf2-small Maf heterodimers and, 74
- reactive oxygen species (ROS) generation, 8–10, 12
- Hydroxylase system, 281
- Hydroxylation, 363
- Hydroxyl radicals
- in aging process, 168
- caloric restriction and, 83, 104–105
- characteristics of, 17–18, 20, 25
- endocrine system, impact on, 262
- honeybee research, 295–296
- mitochondrial diseases, role in, 38
- mollusk research, 377
- neurotraumatic and neurodegenerative disease, role in, 52
- Parkinson disease, role in, 140
- reactive oxygen species (ROS) generation, 3, 10
- 17-Hydroxyprogesterone (17OH-PROG), 123
- Hydroxysteroid dehydrogenase (HSD), 121–122
- 8-Hydroxy-2-deoxyguanosine (8-OHdG), 9, 12
- Hypercholesterolemia, 25–26, 222
- Hyperglycemia, 26, 222
- Hyperinsulinemia, 185
- Hyperoxia, 310
- Hyperphosphorylation, 118, 123
- Hypertension, 12, 23, 88, 213, 215, 222
- Hypertropy, 158
- Hypochlorous acid (HOCl), 153, 295
- Hypoglycemia, 222
- Hypothalamus-pituitary axis (HPA), 122
- Hypoxanthine, 154
- Hypoxia, 22, 175–176, 184, 186, 284, 338, 363–365
- Hypoxia-induced factor-1 (HIF-1), 8, 12, 20, 22, 105–107, 175, 177, 363, 378
- Hypoxia-reoxygenation, 363
- Idiopathic REM sleep behavior disorder, 297
- IGF-I pathway, 351
- I- κ B protein, 8
- Imidazole, 380
- Immune-regulated catalase (IRC), 274
- Immune response, 20, 88
- Immune system, 18, 66, 170–371
- Immunity, social, 283–284
- Immunohistochemistry, 56
- Immunological response, 42
- Immunoreactivity, 52
- Indoles, 141, 143, 252
- Inflammation, 74–75, 83, 110–111, 182. *See also* Inflammatory diseases/disorders; Neuroinflammation
- Inflammatory bowel disease, 310
- Inflammatory diseases/disorders, 111, 272, 310, 379
- Ingenuity Pathways Analysis Systems, 186
- Insecticides, 28, 262, 266, 281–282
- Insects, endocrine control of oxidative stress
- adipokinetic hormones, 264–266
- environmental factors, 266–267
- glutathione S-transferase, 281
- hormones, generally, 264, 266–267
- Insulin
- levels, 20, 87, 89, 201, 222, 251, 285, 317, 341, 351
- resistance, 210–211
- Insulin/IGF-1 pathway, 354–355
- Insulin-like growth factor, 20, 23
- Interferon, 211, 251
- Interleukins
- antioxidants and, 211, 222, 224
- cellular redox regulation and signaling, 203
- free radicals and, 20, 22, 27
- future research directions, 377
- in neurotraumatic and neurodegenerative disease, 54, 106, 110, 112
- Nrf2-small Maf heterodimers and, 66
- reactive oxygen species (ROS) generation, 7
- International Association for the Study of Pain (IASP), 218
- Interstitial fibrosis, 158–159
- Intracellular adhesion molecule-1 (ICAM-1), 7, 54, 111–112
- Intracellular oxidative stress, 175
- Invertebrates
- aging in, 169–170
- Apis mellifera*, 279–289, 295–304
- biomarkers of oxidative stress, 380–382
- Caenorhabditis elegans*, 347–356
- Drosophila melanogaster* studies, 271–276, 309–320, 327–334
- endocrine control, 261–267
- future research directions, 377–382
- mollusks, 361–371
- olfactory dysfunction, 304
- sestrins, 337–342
- Ions/ion transporters, 6, 56
- Iron, generally
- deficiency, 37–38, 185
- induced oxidative stress, 302
- levels, 4, 12, 27, 34, 105, 123, 141–142, 210, 297, 299–301
- regulatory proteins (IRPs), 38, 365
- Irradiation, 23, 74
- Irritable bowel syndrome, 211
- Ischemia, 185
- Ischemia-reperfusion injury (IRI), 12, 157–158, 210, 212–215, 340, 379
- Ischemic brain injury, 41
- Ischemic heart disease, 23
- Ischemic injury, generally, 20, 24
- Isofluorane, 185
- Isoforms, 58–59
- Isofurans, 5, 109
- Isoketals, 5, 109
- Isoprostanes
- caloric restriction and, 92–93, 96
- cardiovascular disease, role of, 155
- free radicals and, 26
- future research directions, 380
- in neurotraumatic and neurodegenerative diseases, 54, 57, 105, 108–109
- in reactive oxygen species (ROS) generation, 5, 8
- Janus kinase (JAK), 21, 133
- JNK protein, 176, 272–276, 286, 364
- Jun-2 proteins, 8
- Juvenile hormones (JHs), 264, 267, 284
- Kainic acid neurotoxicity
- characteristics of, overview of, 51–52
- cholesterol metabolism alterations in, 56–57
- environmental stressors, 184, 186
- glycerophospholipid metabolism alterations in, 52–54
- lipid mediators, interaction consequences, 57–58
- modulation of neurochemical activities in, 52
- neurotraumatic and neurodegenerative diseases and, 58–59
- sphingolipid metabolism alterations in, 51, 54–56
- Keap1
- Drosophila melanogaster* research, 272, 331
- future research directions, 379
- identification of, 67–68
- reactive oxygen species (ROS) generation, 7
- as sensor molecules for electrophiles, 70

- Keap1/Nrf2 system
 characterized, 65–66, 68–70
 controlling longevity, 317
 functional conservation in *Drosophila*, 312–316
 preventing human disease, 309–310
 signaling, 316
- Kearns-Sayre syndrome (KSS), 34, 37, 39–40
- KEGG database, 189
- Keto groups, 57
- Ketonemia, 8
- Ketones, 94, 246, 253
- Kidneys
 caloric restriction and, 94
 environmental stressors, 93, 184–185
 nephropathy, 88
 renal carcinoma, 186, 247
 renal diseases, 20, 24, 225
 renal dysfunction, 36
 tubulointerstitial nephritis, 225
- Klebsiella* spp., 247
- Krebs cycle, 143, 288
- krox-24, 111
- Lactones, 246, 253
- Laryngeal cancer, 248
- Laryngitis, 250
- Late-onset Alzheimer Disease (LOAD), 130
- L-Dopa, 139, 145
- Leber's hereditary optic neuropathy (LHON), 34, 36–37, 39, 41
- Leigh syndrome, 34, 36
- Leptinotarsa decemlineata*, 264–265
- Leptomeningeal melanocytes, 142
- Lesions, implications of, 23, 131, 211
- Letrozole, 124
- Leucine, 188
- Leukemia, myeloid, 39
- Leukoaminochrome (LAC), 143–144
- Leukotrienes, 52, 104, 108, 110
- Lewy bodies (LBs), 26, 28, 139, 141
- Life span, 169–170
- Ligand-receptor signaling, 175
- Ligands, functions of, 20
- Lignans, 212
- Lipid(s)
 functions of, 4, 9, 24, 57–58, 83, 88, 92, 131, 168, 176, 213, 382
 hydroperoxides, 365
 metabolism, 122, 180, 187
 neurodegeneration and, 105
 oxidation of, 18
 peroxidation, 9, 20, 25–26, 90, 93, 95, 117–120, 124, 140, 171, 186, 297, 304, 354
 unsaturated, 53
- Lipoic acid (LA), 9, 94, 209, 354
- Lipopolysaccharides (LPS), 66, 370
- Lipoproteins, 25, 201, 266
- Lipotoxicity, 211
- Lipoxins, 108, 110–111
- Lipoxygenase (LOX), 4–5, 7, 11–12, 66, 104, 106, 110, 117–118, 382
- Liquid chromatography-mass spectroscopic studies, 380–381
- Littorina littorea*, 365
- Liver
 aging process, 171
 diseases of, 223
 environmental stressors, 184–185
 hepatic oxygen, 90
 injury, 74
 nonalcoholic fatty liver disease (NAFLD), 211
 toxicity, 310
 tumors, 66
- LLRK2 gene, 28, 139
- Long-term memory (LTM), 347–348, 350
- Long-term potentiation (LTP), 8
- Lovastatin, 225
- Low-density cholesterol, 25
- Low-density lipoproteins (LDLs), 92, 203
- L-type Ca^{2+} hypothesis, 145–147
- Luciferase, 201
- Luciferin binding protein (LBP), 334
- Lung(s)
 asthma, 221, 272, 310
 cancers, 20, 23, 74
 disease, 175
 environmental stressors, 185
 functions of, generally, 220
 injury, 310, 380
 pleurisy, 74
 pulmonary disease, 310
 pulmonary fibrosis, 310
- Lupus erythematosus, 379
- Lycopenes, 23, 209, 214
- Lymphocytes, 21, 40
- Lymphomas, 220, 339
- Lysine, 41, 108, 381
- Lysophosphatidylcholine (lyso-PtdCho), 108
- Macromolecules, 129, 196, 352
- Macrophages, 3, 74, 203, 223, 338–339
- Macrophagocytes, 284
- Maf proteins
 functions of, 7, 311, 314, 379
 recognition elements (MAREs), 72–73
 regulation of, 73–74
 transcription factor network, 71–74
- Magnesium, 214
- Magnetic resonance imaging (MRI) studies, 215, 352
- Malathion, 266
- Malondialdehyde (MDA), 9, 26–27, 92, 96, 216, 219–220, 266
- Mammalian studies
 neurogenesis, 131
 stress response signaling, 75
- Manganese, 221
- Manganese-dependent superoxide dismutase (Mn-SOD), 34, 39–42, 91, 93, 159–161
- Manganese superoxide dismutase (MnSOD), 84, 89, 93, 124, 154, 158, 169–170, 280–281, 284
- Manganese(III) tetrakis(1-methyl-4-pyridyl)prophyrin (MnTMPyP), 41
- Mantle cells, 369
- Maresins, 108, 111
- Matrix metalloproteinases (MMPs), 54, 159
- MEK1 protein, 25
- MEKK, 21
- Melanin, 275
- Melanoma, 247–248. *See also* Skin cancer
- Melatonin, 212, 218, 251
- Memory, *see* Alzheimer disease; Dementia
 formation of, 8
 impairment, 236, 299
 loss, 57
- Metabolic diseases/disorders, 20, 320
- Metals, *see specific types of metals*
 chelation, 28–29, 210
 health effects of, 22–23, 27, 183, 262
 ions, 17, 175
 redox-active, 4, 12
- Metalloids, 262
- Metalloproteinases (MMPs), 39–40, 111
- Metallothioneins, 94, 171
- Methicillin-resistant *Staphylococcus aureus*, 247
- Methionine, 90, 221, 223–224, 267, 280
- Methionine sulfoxide reductase (MSR), 198
- Methionine35 (Met35), 27
- Methylene group, 109
- Methylmercury toxicity, 319–320
- Methylprednisolone, 184, 186
- Mev-1 gene, 353
- Mianserin, 302
- Michael addition, 108
- Michael adducts, 9, 12
- Microarray analyses, 42, 175, 183, 334, 352, 354
- Microglia/microglial cells, 10, 52, 107, 110–111, 113
- MicroRNA, 280
- Microsomes, 3, 266, 281
- Midlife crisis theory, 355–356
- Miller-Dicker lissencephaly, 111
- Mismatches, 176
- Mito-NAC, 42
- Mito-TEMPL, 42
- Mito-vitamin E, 42
- Mitochondria
 age-related memory impairment, 354
 Alzheimer disease brain and, 302
 dysfunctional, 24–25, 147
 environmental influences, 179–180, 183, 340–341
 functions of, 6, 9, 11, 24, 28, 84–86, 157, 176, 281
 neurosteroids and, 121
- Mitochondrial diseases
 alteration of antioxidant defense system, 39–40
 biochemical consequences of mtDNA, 36–39
 free radicals, 20
 characteristics of, 33–34
 genetics-based gene therapy, 41–42

- heteroplasmy of mtDNA mutations, 35–36
- mtDNA mutation-related, 36
- redox therapy, 40–41
- Mitochondrial DNA (mtDNA)
 - aging process and, 212
 - deletions, 168
 - functions of, 24–25
 - mitochondrial oxidative stress cycle, 34–35
 - neurodegenerative diseases, 107, 113, 125
 - ROS generation, 34, 86
- Mitochondrial encephalomyopathy lactic acidosis and strokelike episodes syndrome (MELAS), 33, 36–37, 39–40
- Mitochondrial permeability transition (MPT), 157
- Mitogen-activated protein kinase (MAPK)
 - Alzheimer disease, role in, 124
 - cardiovascular disease, role in, 160–161
 - Drosophila melanogaster* research, 272
 - endocrine system, impact on, 264
 - free radicals and, 20–22, 24
 - mollusk research, 364, 366, 368–371
 - in neurodegenerative diseases, 105, 109
 - Nrf2-small Maf heterodimer and, 75
 - in reactive oxygen species (ROS) generation 6
- MitoQ₁₀, 41
- Mitosis, 133, 250
- Molecular biology, 334
- Molecular biomarkers, 175
- Molecular genetics, 33
- Molecular oxygen, 84, 262, 295–296, 377
- Mollusks, free radical production, 367
- Mollusks, redox sensing
 - characteristics of, 361–362
 - immune system, 370–371
 - oxygen availability, 362–366
 - pollutant-induced oxidative stress, 366–369
- Monoamine oxidases (MAOs), generally
 - B (MAO-B), 119
 - functions of, 142, 281
 - inhibitors (MAOI), 217, 303
- Monocyte chemoattractant protein 1 (MCP-1), 7, 106, 112
- Motifs, 8. *See specific types of motifs*
- Mouse studies
 - aging process, 170–171
 - Alzheimer disease, 119–120, 124, 302
 - cardiovascular disease, 158
 - environmental stressors, 40–41, 186
 - neurogenesis, 132
 - Nrf2 signals, 320
 - Nrf2-small Maf heterodimers, 64–74
 - olfactory dysfunction, 299
 - Parkinson disease, 141–142, 145, 317–318
 - selenoproteins, 200–201
 - sesstrin homologs, 338–339
 - wine consumption benefits, 237–240
- MPTP, 141–142, 145–146
- Mucosa-associated lymphoid tissue (MALT) lymphoma, 220
- Multiple Elm for Motif Elicitation (MEME) motifs, 329–330, 332–333
- Multiple sclerosis (MS), 111, 215, 221, 297
- Musashi1, 133
- Musculapneurotic fibrosarcoma oncogenes, 7
- Muscular dystrophy syndromes, 203
- Mutagenesis, 19, 382
- Mya arenaria*, 368
- Mycobacterium* spp., 247
- Myeloperoxidase, 3, 12, 104, 370, 382
- Myocardial infarction, 41, 214
- Myocardial ischemia-reperfusion, 364
- Myocardium, 157
- Myoclonic epilepsy with ragged red fibers (MERRF), 34, 36–37, 39–40
- Myocytes, 160, 184
- Mytilus* spp., 364, 368–370
- N*-acetylcysteine (NAC), 39–40, 224–225
- NADPH
 - environmental stressors and, 183, 187
 - functions of, 154–155, 158–160
 - neurosteroids and, 121
 - oxidase, 4–5, 7, 10, 12, 20, 24, 26, 55, 57–58, 104–106, 109, 112, 183, 377
 - oxidation of, 288, 302
 - quinone oxidoreductase 1 (NQO1), 65, 309
 - redox sensing, 370
 - ROS production, 261, 274
 - selenoproteins and, 198
- NASH, 220
- National Center for Biotechnology Information (NCBI), 328–329
- Necrosis, 12, 19–20, 23
- Neoepitopes, 12
- Neogenesis, 124
- Nephropathy, 88
- Nerve growth factor, 251
- Nervous systems, influences on, 187, 273. *See also* Central nervous system (CNS)
- Nestin, 133
- Neural cells, ROS role in
 - cell death, 8–9
 - cognition, 8
 - enzyme activities, 6
 - gene modulation, 6–8
 - long-term potentiation (LTP), 8
 - memory formation, 8
 - overview of, 4–6
 - transcription factors, 6
- Neural loss, 352
- Neural membrane, oxidative stress-mediated damage to, 107–110
- Neural stem cells (NSCs), 129, 131
- Neuroblastoma cells, 119, 124, 319
- Neurodegeneration
 - Alzheimer Disease (AD) and, 131
 - dopaminergic, 145
- influential factors, generally, 3, 9, 11, 103, 133, 341
- Parkinson disease (PD), 139–140
- Neurodegenerative diseases, *see specific types of neurodegenerative diseases*
- antioxidant therapy, 210–212, 215–218
- Caenorhabditis elegans* research, 353, 356
- Drosophila melanogaster* research, 273, 317
- environmental factors, 104, 175
- future research directions, 379–380
- genetic factors, 104
- inflammation, 110–111
- interplay among excitotoxicity, oxidative stress, and neuroinflammation, 111–112
- kainic acid neurotoxicity, 58–59
- mitochondrial diseases, 34
- oxidative and nitrosative stress in, 104–110
- reactive oxygen species (ROS) generation, 10–12
- types of, 6, 103–104, 112–113, 317–318
- Neurodegenerative disorders, 85, 215–218, 310
- Neurofibrillary tangles (NFTs), 118, 120, 130–132, 134, 215–216, 236
- Neurofurans, 5
- Neurogenesis, 112, 187
- Neurogenic muscle weakness, ataxia, retinitis pigmentosa (NARP), 34
- Neurohormones, 28, 264
- Neuroinflammation, 103–105, 110–113, 352–354
- Neuroketals, 5
- Neurological diseases, 24
- Neurological disorders, development of, 26. *See also* Alzheimer disease (AD); Parkinson disease (PD)
- Neurological disorders, 20
- Neuromelanin, 143
- Neuronal disorders, 190
- Neuronal injury, 6
- Neuronal loss, 317–318
- Neuropathic pain, 122
- Neuropathy, 36, 210
- Neuropeptides, 264
- Neuroplasticity, 112
- Neuropolypeptide h3, 107
- Neuroprostanes, 5, 109
- Neuroprotectins, 111
- Neuroprotection, 106, 108, 122, 124–125. *See also* Neurosteroids
- Neuropsychiatric disorders, 297
- Neuroskeletal system, 109
- Neurosteroidogenesis, 117, 123–124
- Neurosteroids
 - biosynthesis, 117, 120–122
 - characteristics of, 120
 - mechanisms of action, 122
 - oxidative stress and, 122–125
- Neurotoxicity, 107, 144–145, 236
- Neurotoxins, parkinsonian, 141
- Neurotransmitters, 28, 52, 57, 122, 132, 216, 251

- Neurotraumatic diseases, 10–11, 58–59, 111–112
- Neurotrophins, 251
- Neutrophils, 3
- Nickel, health effects of, 20, 22
- Nicotinamide adenine dinucleotide (NADH), 84, 140
- Nicotinamide adenine dinucleotide (NADH)-ubiquinone oxidoreductase, 34
- Nitric oxide (NO)
- in aging process, 154–155, 160
 - caloric restriction, effect on, 92
 - environmental stressors, 175–176, 178–179
 - free radicals and, 18, 20, 22, 25–26, 28–29
 - future research directions, 379
 - honeybee research, 299
 - mollusk research, 363, 368, 370–371
 - in neurodegenerative diseases, 107, 113
 - Parkinson disease, role in, 140
- Nitric oxide synthase (NOS)
- Alzheimer disease, role in, 140
 - antioxidants and, 220
 - caloric restriction and, 85–86
 - cardiovascular disease, role in, 154
 - isoforms (iNOS), 93, 111, 146, 159
 - mollusk research, 364
 - in neurotraumatic and neurodegenerative diseases, 54, 57–58, 106–107, 112
 - Nrf2-small Maf heterodimer, 66
 - reactive oxygen species (ROS) generation, 4–5, 7–8, 11
- Nitrogen levels, 83, 221
- Nitrooleic acids, 107
- Nitrosative stress, 11, 104–110
- Nitrosylation, 9–10, 107, 140, 198, 200, 204
- Nitrotyrosine, 10, 26, 92, 103
- N*-methyl-D-aspartate receptor (NMDAR), 52, 122, 125, 143, 199, 353
- Nonenzymatic scavengers, 94–96
- Non-small-cell lung cancers, 20
- Nonsteroidal antiinflammatory drugs (NSAIDs), 354
- Nonviral vectors, 43
- Norepinephrine (NE) levels, 143, 251
- Normal aging, 12, 352–353
- Novel motifs, 329, 331
- Nrf2, *see* Keap1/Nrf2 system; Nrf2-small Maf heterodimer survival strategy and disease pathogenesis
- degradation of, 69–70
 - Drosophila* as model organism for study of, 313–320
 - dysfunctional, 74–75
 - electrophile-independent activation of, 71
 - future research directions, 379–380
 - functions of, generally, 7–8, 105, 175, 264
 - heterodimerization, 72
 - in honeybees, 295
 - identification of, 63–64
 - inducers, 67
 - inhibitors of, 75
 - methylmercury toxicity, 319–320
 - mutations, 71
 - neurodegenerative disease and, 106–107
 - promoter analysis study of circadian regulatory motifs, 331
 - in protection from Parkinson disease 9PD), 317–319
 - post-translational modification of, 71
 - as target of Keap1, 68–69
- Nrf2-small Maf heterodimer survival strategy and disease pathogenesis
- CNC-small Maf transcription factor network, 71–74
 - DNA sequences, 72–73
 - dysfunctional Nrf2 in pathology, 74–75
 - identification of Nrf2, 63–64
 - Keap1-nrf2 system in response to electrophiles, 65–71, 272
 - phenotypes, 66
 - susceptibility of Nrf-2 null mice to oxidative and xenobiotic stress, 64–65
- Nuclear DNA (nDNA), 24, 33
- Nuclear factor of activated T-cells (NFAT), 22
- Nuclear factor erythroid 2 related factor 2. *See* Nrf2
- Nuclear factor kappa B (NF- κ B)
- Alzheimer disease, role in, 124
 - antioxidants and, 211
 - caloric restriction and, 84, 86
 - cardiovascular disease, role in, 161
 - Drosophila melanogaster* research, 274
 - endocrine system, effect on, 264
 - environmental stressors, 175–177, 181–182
 - free radicals and, 20, 22–23, 26
 - future research directions, 377, 380
 - honeybee research, 295
 - in neurotraumatic and neurodegenerative diseases, 53, 55, 105–107, 111
 - Nrf2-small Maf heterodimer, 66
 - reactive oxygen species (ROS) generation, 5, 8, 11–12
- Nuclear magnetic resonance (NMR) spectroscopic studies, 201
- Nucleic acids, 107, 131, 168
- Nucleophiles, 144
- Nurses' Health Study, 217
- Nutrition. *See* Food and diet; Parenteral nutrition; Total parenteral nutrition (TPN)
- Nutritional Prevention of Cancer, 219
- Obesity, 86, 211, 213, 341
- Octadecenoic acid, 107
- Octapine, 301
- Octopamine, 299, 302
- Octreotide, 184, 186
- Oleic acids, 107
- Olfactory dysfunction, 297–298, 302–303
- Olfactory learning
- honeybee research, 298–299, 301
 - memory and, 349–350
- Olfactory processing, honeybees and humans compared, 298
- Oltipraz, 75
- Organ fibrosis, 20
- Ornithine, 11
- Osteoarthritis (OA), 225
- Ovalbumin, 66
- Ovarian cancer, 20
- Oxidative metabolism, 354
- Oxidative phosphorylation system (OXPHOS) system
- Alzheimer disease (AD) and, 119
 - defects in, 36–37
 - deficiency, 42
 - honeybee research, 297
 - mitochondrial diseases, 34, 37, 40
- Oxidative strength, 112
- Oxidative stress, generally
- autocatalytic cycle, 88
 - basic characteristics of, 83–84
 - defenses against, 262–264
 - defined, 3
 - endogenous sources of, 261–262
 - exogenous sources of, 262
- Oxidoreductase, 19
- 4-Oxo-trans-2-nonenal (4-ONE), 28
- Oxycholesterols, 56–57
- Oxygen conformity, 363
- Oxygen
- functions of, generally, 20, 27
 - consumption rate (OCR), 37
 - hepatic, 90
 - molecular, 84, 262, 295–296, 377
 - O₂ sensing, 363–364
 - reactive, *see* Reactive oxygen species (ROS)
 - redox sensing, mollusk research, 362–366
- Oxyradicals, 55
- OXY-SCORE index, 95
- Oxysterols, 57
- Pancreas, 184, 211
- Pancreatic cancer, 21–23
- Pancreatitis, 223–225
- Paraoxonase I (PON1), 91, 94
- Paraquat, 141–142, 145, 171, 262, 265–267, 313, 317–318
- Parasitoids, 275
- Parenteral nutrition (PN), 221
- Parkin, 28, 319
- Parkinson disease (PD)
- antioxidant therapy, 215, 217
 - brain dysfunction, 341
 - caloric restriction and, 85
 - Drosophila melanogaster* research, 273, 310
 - free radicals and, 26, 28
 - future research directions, 379
 - honeybee research, 297
 - mitochondrial DNA (mtDNA), role in, 34, 38, 41
 - neurosteroids and, 117
 - olfactory dysfunction, 297, 302–303
 - overview, 139–140
 - oxidative stress and, 139–146

- pathogenesis, 58, 103, 105, 107, 111, 132, 317–318
 protective substances, 317–318
 reactive oxygen species (ROS), 6, 140
 therapeutic implications, 146–147
 Parkinsonism, 318
 Parkinsonism-complex disease (PCD), 297
 PC12 cells, 119
 PDGF receptor (PDGFR), 20
 p85, 22
 Peptides, functions of, 27, 41. *See also specific types of peptides*
 PER-ARNT-SIM (PAS) protein, 327
 Peripheral arterial disease (PAD), 215
 Peripheral mononeuropathy, 210
 Peripheral-type benzodiazepine receptor (PTBR), 121
 Perkin, 107
 Permeability transition pores (PTPs), 11
 Permethrin, 266
 Peroxidases (POs), 142, 283, 337
 Peroxidation, 3, 5, 10, 108, 113, 266
 Peroxiredoxin (Prx), 2, 41, 107, 143, 176–178, 271, 273, 337, 339
 Peroxisome proliferator-activated receptor (PPAR), 89
 Peroxisomes, 3
 Peroxyl radicals, 3, 52, 83, 104–105, 263, 295, 377
 Peroxynitrate, 85
 Peroxynitrite (ONOO⁻)
 Alzheimer disease, role in, 117, 129
 caloric restriction, effect on, 85
 cardiovascular disease, role in, 153
 cellular redox regulation and signaling, 196
 free radicals and, 18, 24–27
 future research directions, 379–380
 honeybee research, 299
 mitochondrial DNA (mtDNA) and, 34
 mollusk research, 364
 in neurotraumatic and neurodegenerative diseases, 54, 107
 Parkinson disease, role in, 140, 143
 reactive oxygen species (ROS) generation, 7, 12
 Peroxyredoxins, 309
 p53 gene
 environmental stressors, 175–176, 178, 186–190
 free radicals and, 20, 22
 mollusk research, 368
 in neurodegenerative disease, 105
 sestrins and, 337–339
 pH, significance of, 18–19
 Phagocytes, 140, 283, 370
 Phagocytosis, 281, 283, 370
 Phenolic acids, 212, 214, 237–239, 246, 253
 Phenol oxidases (POs), 275
 Phenoloxidase system (POS), in insects, 282–284
 Phenoxyl radicals, 262
 Phenylalanine, 41
 Phenylephrine, 74
 Phosphatases, 8
 Phosphatidylcholines, 104
 Phosphatidylinositol-3, 355
 Phosphatidylinositol-3 kinase, 124
 Phosphoglycerate mutase1, 107
 Phospholipase A₂ (PLA₂)
 Alzheimer disease, role in, 117
 future research directions, 378, 380
 honeybee research, 302–303
 in neurotraumatic and neurodegenerative diseases, 52–55, 58–59, 106–108, 111–112
 reactive oxygen species (ROS) generation, 9
 Phospholipases
 C (PLC), 8, 274
 C (PLC)/diacylglycerol (DAG) lipase pathway, 52
 functions of, 4–5, 8, 111
 Phospholipids, 5–6, 12, 58, 103, 140, 203, 216, 377
 Phosphorylation
 Alzheimer disease, role in, 124
 environmental stressors and, 176
 free radicals and, 21–22
 mollusk research, 366, 368
 in neurodegenerative diseases, 108
 Nrf2-small Maf heterodimers, 71, 75
 in propolis, 251
 in reactive oxygen species (ROS) generation 6–8
 sestrins and, 340–341
 Phytochemicals, 212, 214
 Phytoestrogen, 89
Planococcus citreus, 370
 Plaques, in Alzheimer disease
 amyloid, 129–132, 216
 A β , 120
 senile, 112, 118
 Platelet-activating factor (PAF), 4, 7, 104, 108, 111
 Platelet-derived growth factor (PDGF), 7, 20, 24
Podospira spp., 169
 Point mutations, 36
 Points of Care, 210
 Pollution, health effects of, 319, 366–369
 Poly(ADP-ribose) polymerase (PARP), 11–12, 88, 107, 252
 Polychlorinated biphenyls (PCBs), 367
 Polycyclic aromatic hydrocarbons (PAHs), 367
 Polymorphonuclear cells (PMNs), 220
 Polyols, 263
 Polypeptides, 34, 42
 Polyphenolics, 240–241
 Polyphenols, 22–23, 84, 209, 213
 Posttranslational modification, 71, 367
 Potassium (K⁺), 4
 Prednisolone, 223
 Pregnancy, preeclampsia and, 221
 Pregnenolone (PREG), 120–122, 185
 Presenilins (PSEN), 118–119, 130, 132, 134, 352
 Primate studies
 aging process, 352
 caloric restriction, 88, 92
 neurogenesis, 131
 selenoproteins, 200–201
 Prion diseases, 103, 111
 Proboscis extension reflex (PER)
 conditioning, 297
 Probutol, 222
 Progenitor cells, 133
 Progesterone (PROG), 117, 121–122, 124
 Proinflammatory cytokinases, 110
 Proinflammatory cytokines, 5, 27, 104, 106, 113, 211, 224, 377
 Proinflammatory enzymes, 5, 106
 Proliferator-activated receptor (PPAR), 107
 Promoter analyses, 74, 328–334
 Prooxidant effect, 124
 Pro-phenol oxidases (PPOs), 275
 Prophyrin (P), 41
 Propolis (bee glue)
 cellular signal transduction, 250–252
 commercial use of, 253
 composition, 246
 food safety, 246
 historical perspective, 246
 human nutrition, 246
 overview, 245–246
 therapeutic properties, 246–250
 toxic effects, 252–253
 Prostaglandins (PGs)
 caloric restriction, effect on, 92–93
 in neurotraumatic and neurodegenerative diseases, 52, 57, 104, 108, 110
 Nrf2-small Maf heterodimers and, 74
 PGC-1 α , 40
 PGD₂, 111
 PGF₂, 109
 PGG, 109
 PGJ₂, 111
 Prostate cancer, 20, 23, 219, 247–248, 339
 Prostate, Lung, Colorectal, and Ovarian Cancer Screening Tool, 219
 Proteasomes, 104, 107
 Proteinases, 110
 Protein error theory, 168
 Protein kinases
 A (PKA), 109
 B, *see* Akt
 C (PKC), 24, 26, 86–87, 124, 133, 370
 functions of, 8
 Protein phosphatases, 6
 Proteins, *see specific types of proteins*
 acute-phase, 112
 Alzheimer Disease and, 131
 deficiency, 72
 detoxification, 280
 environmental stressors, 179, 184, 186
 functions of, generally, 83, 88, 168, 176

- Proteins, *see specific types of proteins*
(*continued*)
hemolymph, 266
misfolded, 103, 107, 112
oxidation, 90, 124
redox-responsive, 6
redox sensing, 367
redux environment, 19
scaffolding, 7
stress-responsive, 6
synthesis, 34, 107
- Protein tyrosine
kinases (PTKs), 6, 20–21
phosphatases (PTPs), 20–21
- Proteomes, 88, 175
- Proteomics, 381–382
- p62 gene, 317
- Psoriatic arthritis, 379
- PTEN-induced putative kinase 1 (PINK-1),
28, 139, 142
- p13, 20, 264
- p38 gene, 6, 21, 24, 133, 160, 272, 364,
368–369
- P2X receptors, 122
- p21 gene, 23
- Purkinje neurons, 352
- Pyrrhocoris apterus*, 265–266
- Pyruvate, 40
- Pyruvate dehydrogenase
complex (PDHC), 40
kinase (PDK), 40
- Quercetin, 23, 209, 214, 252
- Quinacrine, 53
- Quinines, 246, 253
- Quinones, 141–142, 144, 158, 196, 302
- Radiotherapy, 74, 220, 248
- RAF, 21
- Ragged red fibers (RRFs), 37, 39
- RANTES, 251
- Rapamycin, 341–342
- Raspberries, antioxidant studies, 211–212
- Rat studies
caloric restriction, 90–93, 95
environmental stressors, 183–186
neurotoxicity, 51–54
peroxidation in brain, 300
propolis properties, 250
- Reactive nitrogen species (RNS)
cardiovascular disease and, 153
cellular metabolism and, 261
environmental stressors and, 140, 175
free radicals and, 17–18, 20, 22–24, 26, 28
future research directions, 382
neurodegenerative diseases, 107
- Reactive oxygen metabolites (ROMs),
220–221
- Reactive oxygen species (ROS)
aging process and, 356
aging theories, 168–169
Alzheimer disease and, 129, 133
association with disease, 220–221
in brain
chemical reactivity of, 3
production of, 3–4
role in neural cells, 4–9
characteristics of, 83
cellular sources of, 261
dual character of, 28–29
environmental stressors and, 175, 177
formation/generation of, 84–88
future research directions, 377–382
human disease and, 20–26
hypoxia and, 362–363
in member rafts, 58
mitochondrial, 92
mitochondrial DNA (mtDNA), 34
neurodegenerative diseases and, 140,
215–218
Nrf2 and, 65
oxidative stress-mediated signaling
pathways, 176
redox sensing, 361–371
- Reacylation, 5–6
- Receptor for AGE (RAGE), 87–88, 156
- Rectal cancer, 23. *See also* Colorectal cancer
- Redox factor-1 (Ref-1), 264
- Redox potential, 198–200
- Redux environment, 18–20
- Reperfusion injury, 24, 41
- Reproductive disorders, 175
- Reproductive system, 187
- Resolvins, 108, 111
- Respiratory infection, 250
- Respiratory system, 187
- Resveratrol, 84, 89, 209, 214, 252
- Retinoic acids, 175
- Retinoic X receptor ligand, 184, 186
- Retinopathy, 223
- Rheumatoid arthritis, 211, 225, 272, 379
- Rhinitis, 250
- Riboflavin, 223
- Ribonucleic acid. *See* RNA
- RNA
double-stranded (dsRNA), 314–315
functions of, 91, 113, 176
import complex (RIC), 42
interference (RNAi), 280, 312, 315, 319
messenger (mRNA), 195, 202, 312, 315,
318, 327, 331, 334, 352, 355, 363, 365
metabolism, 181
oxidation, 140, 297, 299
oxidized, 118–119
synthesis, 54, 108
transfer RNA (tRNA), 33, 36, 42, 195–196
- Rodent studies, *see* Mouse studies; Rat
studies
normal aging, 353
selenoproteins, 200–201
significance of, 88
- Rosiglitazone, 339
- Rotenone, 141
- Ruditapes decussatus*, 367
- Saccharides, 83, 88
- Saccharomyces cerevisiae*, 169, 247, 274,
338, 341
- Salmonella*, 247
- SAME supplements, 223–224
- Sandelin-Wasserman similarity function, 329
- Sarcolemma, 24
- Scavenger enzymes, 84, 93–94, 112, 145, 196
- Schizophrenia, 297
- Sec insertion sequence (SECIS), 195–196,
202
- Secondary radicals, 17
- Securin, 338
- Selectin, 111
- Selegiline, 217
- Selenium (Se), 39, 217, 214, 220,
224–225, 288
- Selenoproteins
defined, 195
families, 201–203
functions of, 6, 195–196, 217
future research directions, 203–204
oxidative stress and, 196–198
redox systems, 198–200
synthesis, 196
in vertebrate signaling, 200–201, 204
- Senescence, 167
- Sepsis, 66
- Serine
functions of, 22
kinases, 251
palmitoyltransferase (SPT), 55
/threonine phosphatases (PP2A), 8
/threonine protein kinase, 331
- Serotonin levels, 251, 351–352, 354
- Sestrins
characteristics of, 337–338
chemical induction of, 339
deficiency and age-related pathologies,
341–342
homologs, 338–339, 342
nervous system effects, 339
as redox regulator, 339–340
regulation of expression by stresses,
338–339
as TORC1 suppressor, 341
- SH-SY-5Y cells, 119, 123–124
- Shark liver oil (SLO), 211
- Short-term memory (STM), 347–348, 350
- Signaling networks, intracellular, 6
- Signaling pathways, oxidative
stress-mediated
environmental stressors, rat studies,
183–186
overview of, 177–183
p53 pathways in human tissues, 186–190
- Signal transduction
functions of, 176, 180, 367
human disease and, 20–26
pathways, 170
receptors, *see* Signal transduction
receptors
ROS generation and, 8–10, 12
- Signal transduction receptors
classification of, 251
signaling molecules, 251–252
- Single nucleotide polymorphisms (SNPs), 65

- Sirtuins, 88–89
 Skeletal muscle, 122, 184, 339, 341–342
 Skin
 cancer, 219
 contact dermatitis, 252–253
 infection, 249
 Nrf2 gene and, 66
 vitiligo, 310
 SKN-1 transcription factor, 317, 319–321
 SMAD protein, 181
 Small molecule biochemistry, 187
 Smooth muscle, 18, 109
 Sniffer protein, 329, 331
 S-nitrosoglutathione (GSNO), 364, 366
 SNO-Drp1, 107
 Sodium barbitol, 158
 Sortilin, 130
 Spatial memory, 352
 Sphingolipids, 12, 51–52, 54–56, 103, 110
 Sphingomyelinases (SMases), 10–11, 109–110
 Sphingosine kinase 1 (SPHK1), 55–56
 Spinal cord
 functions of, 122
 injury (SCI), 58, 111, 132
 trauma, 6
 Spinogenesis, 122
Spodoptera littoralis, 262
 Squalene, 211
 Staining
 cholesterol, 56
 immunocytochemical, 53
 immunohistochemical, 132
Staphylococcus spp., 247, 250
 Starvation-odor association, 350
 STAT proteins
 functions of, 133
 Stat3, 75
 Statins, 55, 157
 Stem cells, mesenchymal, 89
 Stereology, 132
 Steroid hormones, 264, 266
 Steroidogenesis, 120–121
 Steroids, 121, 246, 251, 253
 Sterol regulatory element binding proteins (SREBPs), 105
 Sterol-responsive binding protein (SREBP), 340
 Sterols, 168
 Stomach cancer, 23
Streptococcus spp., 247
 Streptokinase, 214
Streptomyces lividans plasmid 1 (SLP1), 66
 Streptozotocin, 184, 186
 Stress-activated/c-Jun NH₂-terminal kinases (SAPK/JNKs), 24
 Stroke(s)
 antioxidant treatment, 214
 cerebral, 132
 etiology, 6, 58, 111
 risk factors, 213
 Substantia nigra pars compacta (Snc), 28
 Succinate
 dehydrogenase (SDH), 37–38
 -ubiquinone oxidoreductases, 34
 Sucrose, 92. *See also* Sugars
 Sugars, 168, 246, 253
 Sulfate, 225
 Sulfation, 281
 Sulfenic acid, 198
 Sulfhydration, 198, 204
 Sulfhydryl groups, 20, 24, 107, 380
 Sulforaphane, 75
 Sulfotransferase, 281
 Sulfur, 195
 Sulfur dioxide, 184, 186
 Superfamilies, 176
 Superoxide anions
 caloric restriction, effect on, 83
 cardiovascular disease, role in, 158
 endocrine system effects, 261–262
 free radicals and, 24, 27
 future research directions, 377
 honeybee research, 299
 mitochondrial diseases, 34
 in neurotraumatic and neurodegenerative diseases, 52, 104, 107
 reactive oxygen species (ROS) generation, 3
 radical, 261, 279, 295
 Superoxide dismutase (SOD)
 in aging process, 168, 170
 Alzheimer disease, role in, 117, 119, 129
 antioxidants and, 284
 caloric restriction, effect on, 84, 86, 90, 95
 cardiovascular disease, role in, 154
 Drosophila melanogaster research, 271, 273, 276, 331
 endocrine system effects on, 263, 266
 environmental stressors, 175–177, 188
 free radicals and, 17, 23, 25–26
 honeybee research, 284, 295
 in mitochondrial diseases, 34, 39–41
 mollusk research, 370
 in neurotraumatic and neurodegenerative diseases, 54, 59, 103, 112
 Parkinson disease, role in, 140, 143
 reactive oxygen species (ROS) generation, 3, 5–6, 8–10
 sestrins and, 337, 355
 Superoxide radicals, 17, 24–26, 83, 95
 Synapses
 synaptic dysfunction, 103
 synaptogenesis, 122
 Systemic lupus erythematosus (SLE), 12
 Szeto-Schiller (SS) peptides, 41
 Tachycardia, 157
 TAK, 21
 Tandem mass spectrometric studies, 54
 Tannins, 212
Tapes phillipinarum, 368
 Target of rapamycin (TOR), 340. *See also* TOR complexes (TORC1/TORC2)
 Tauopathies, 297
 Tau protein, 118–120, 123, 130–131, 134, 236
 Telmisartan, 222
 Testosterone, 121
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD), 175
 TGF- β -BMP signaling, 176–177, 181
 Thermodynamics, 18
 Thermotaxis
 Caenorhabditis elegans research, 353–354
 learning and memory, 349–351
 Thiobarbituric acid (TBA), 92
 Thiols, 11, 19, 22, 196, 204, 367
 Thionein, 198
 Thioresoxin (TXN)
 antioxidants and, 217, 279
 cellular redox regulation and signaling, 197–203
 Drosophila melanogaster research, 309, 329
 endocrine system effects, 263, 272
 free radicals and, 19
 honeybee research, 279
 in mitochondrial diseases, 41
 peroxidase (TPX), 280, 288
 reactive oxygen species (ROS) generation, 6
 thioredoxin reductase system, 380
 Threonine
 functions of, 21–22
 kinases, 251
 Thrombolytic therapy, 157
 Thromboxanes, 52, 54, 104, 108, 110
 Thyroid hormones, 200–201
 Tin (Sn), health effects of, 195
 Tinidazole, 249
 Tissue(s)
 oxidative damage to, 37, 42–43
 regeneration, 75
 TNF- α
 antioxidants and, 211, 224
 cellular redox regulation and signaling, 203
 environmental stressors, 176
 future research directions, 377
 in neurotraumatic and neurodegenerative diseases, 52, 54, 106, 110–112
 Nrf2-small Maf heterodimer, 66
 reactive oxygen species (ROS) generation, 7–8
 Tocopherols, 209, 218. *See also* α -Tocopherols
 Toll-like receptor 3 (TLR3), 288
 TOR complexes (TORC1/TORC2)
 defined, 340
 functions of, 337–338
 hyperactivation, 342
 induction of stress-associated pathologies, 340–341
 signaling, 340
 suppression of, 341
 Total body mass, 8–9
 Total internal reflection fluorescence microscopy (TIRFM), 57
 Total parenteral nutrition (TPN), 224

- Toxins
 environmental, 28
 neurotoxins, 141
- Transcription factors (TF)
 activation of, 52
 cellular redox regulation and signaling, 199
 Drosophila melanogaster research, 311, 327, 333
 environmental stressors, 175–176, 180–181, 183
 free radicals and, 22–23
 honeybee research, 296
 Maf network, 71–74
 neurodegeneration and, 105–107
 neurogenesis, 131
 reactive oxygen species (ROS) generation, 6–8
- Transcription regulators, 179, 182
- Transcription start site (TSS), 328–329
- Transferrin, 94, 263, 267
- Transferrin receptor (TfR1), 38–39
- Transforming growth factor, 175
- Transient receptor potential (TRPA1), 107
- Transition metals, 25, 168
- Translation, cotranslational, 42
- Translocation, 8, 106, 179, 199
- Translocator protein (TSPO), 121
- Transnitrosylation, 364
- Transporters, modulation of, 52
- Traumatic brain injury (TBI), 6, 58, 132
- Traumatic head injury, 111
- Tricarboxylic acid (TCA), 38, 54, 125
- Trimethylin, 184, 186
- Triose phosphate isomerase, 107
- Triphenylphosphonium (TPP), 41
- Triterpenoids, 75
- Troponin I, 157, 162
- Tryptophan, 9
- Tumeric, health effects of, 211
- Tumor(s)
 caloric restriction, effects of, 83, 88
 cerebral, 186
 free radicals and, 19
 mammary, 184
 Nrf2-small Maf heterodimers ad, 66, 75
 promoters, 23, 183
 suppressors, 186
- Tumor growth factor (TGF), 21, 176
- Tumor necrosis factor (TNF), *see* TNF- α
 environmental stressors, 175, 183
 free radicals and, 20, 22, 26
 ligand-receptor signaling, 176, 183
- Two-hit hypothesis, 133
- Type 2 diabetes, 85, 92. *See also* Diabetes;
 Insulin levels
- Tyrosinase, 142
- Tyrosine
 functions of, 21, 27, 41, 72
 kinase inhibitors (TKIs), 20
- kinases, 251
 methionine, 9
 phosphatases, 251
- Ubiquinol-cytochrome *c* oxidoreductase, 34
- Ubiquinone, 34, 95, 209. *See also*
 Coenzyme Q
- Ubiquitin, 142, 317
- Ubiquitination, 310
- UDP glucuronate transferases (UGT), 65
- UDP-glucose:glycoprotein
 glucosyltransferase (UGTR), 203
- UDP-glucosidase, 281
- Ulcerative colitis (UC), 211, 249
- Ulcers, 211, 220, 310
- Uncoupling proteins (UCPs), 25, 84–85, 90, 362–363
- Untranslated region (UTR), 196
- Up-genes, environmental stressors, 184–186
- Upregulation, 5, 22, 42, 52, 106, 112, 123, 183, 272, 338–339, 365
- Uric acid, 84, 94, 263
- UV-B irradiated cells, 23
- UV radiation, 21–22
- Vaccines, 249
- Vanin-1, 288
- Vascular adhesion molecule-1
 (VCAM-1), 54, 109, 111–112, 156, 378
- Vascular endothelial growth factor (VEGF), 20, 22, 133, 160–161, 252
- Vascular smooth muscle cells (VSMCs), 7
- VEGF receptor (VEGFR), 20
- Vertebrates
 aging in, 167–171
 Alzheimer disease, 117–125, 129–134
 antioxidant therapy, 209–226
 biomarkers of oxidative stress, 380–382
 caloric restrictions, 83–96
 cardiovascular disease, 153–162
 environmental stressors, 175–190
 free radicals, 17–29
 future research directions, 377–382
 kainic acid neurotoxicity, 51–59
 mitochondrial DNA mutations, 33–43
 neurodegenerative diseases, 103–113, 235–242
 Nrf2-small Maf heterodimers, 63–75
 olfactory dysfunction, 304
 Parkinson disease, 139–147
 propolis research studies, 245–253
 reactive oxygen species (ROS), 3–12, 283
 redox regulation and signaling, 195–204
 selenoproteins in, 200–201
 signal transduction, 17–29
- Vibrio* spp., 370
- Viral vectors, 43
- Viruses
 herpes virus, 247, 250
 human immunodeficiency virus (HIV), 111, 220
 influenza virus, 247
 Newcastle disease virus, 247
 potato virus, 247
 propolis treatment of, 247
- Vitagenes, 380
- Vitamin(s), functions of
 A, 210, 213–214, 217, 253
 B, 40, 210, 253
 B6, 223
 C, 18–19, 23, 28, 40, 42, 113, 156, 212–225, 253, 379
 overview of, 84, 246, 253
 E, 6, 9, 18, 22–23, 26, 28, 42, 113, 210, 212–217, 219–225, 253, 342
 K, 40, 42
- Vitamin supplementation, 120
- Vitellogenins, 267, 284–285
- Voltage-dependent anion channels
 (VDACs), 37, 143
- WAFI, 23
- Wild-type APP (wtAPP), 119, 123–124
- Wilson disease, 34
- Wine, treatment of Alzheimer disease, 236–242
- Women's health
 breast cancer, 21, 23, 74, 247–248
 contraception, 213
 endometriosis, 220
 estrogens, 91, 123–125, 142, 220
 hormone replacement therapy, 213
 menopause, 220
 ovarian cancer, 20
 pregnancy and preeclampsia, 220–221
- Woman's Health Initiative Memory Study
 (WHIMS), 124
- Working memory, 348, 352
- Wound healing, 248–249, 253
- Xanthine
 dehydrogenase, 24
 functions of, 3, 12, 154
 oxidase (XOD), 3, 12, 24, 26, 104, 168, 220, 261, 382
- Xenobiotic(s)
 -activated receptors (XARs), 264
 functions of, 175, 281, 367
 stress, 64–65, 67
- Xenopus*, 339
- Yeast, *see Saccharomyces cerevisiae*
 cells, 169
 infection, 249
 mitochondrial diseases, 41
- Zebrafish studies, 203
- Zinc (Zn), 27, 74, 119, 214, 220, 223, 280, 368